A New Zealand researcher has been recognised for a major breakthrough in the treatment of a virus which causes liver failure.
Professor Edward Gane was one of more than a dozen researchers and
scholars awarded medals by the Royal Society of New Zealand at a
ceremony in Wellington last night.
Professor Gane, from Auckland City Hospital and the Auckland District
Health Board, received the Liley Medal for his work on an improved
treatment for hepatitis C, which is a major cause of liver failure in
People at risk of the disease could be screened in community pharmacies
that already offer needle exchange or methadone services.
Community pharmacists have the potential to screen at-risk groups for
hepatitis C and could play a key role in helping to improve liver
disease services in primary care, according to the conclusions of a
commission set up to investigate the impact of the disease.
Writing in The Lancet (online, 27 November 2014),
the group of leading doctors and medical scientists who made up the
commission argue that screening for hepatitis C in primary care is
People at risk of the disease could be screened in community
pharmacies that already offer needle exchange or methadone services,
suggests the group, led by Roger Williams, director of the institute of
hepatology at Foundation for Liver Research, London.
What’s the price of a human life? Many of us would say each life is
priceless. But health economists sometimes have a number in mind.
Want to know what that number is?
this part of our series “At the Crossroads: The Rise of Hepatitis C and
The Fight To Stop It,” we’ll tell you that – and more. We go beyond the
high price of new hepatitis C drugs to ask: how much is too much? And
what the heck is a “quality adjusted life year” anyway?
The city’s medical services director, Dr. James Dunford told a City
Council committee Nov. 13 that more than 2.5 million dirty needles were
properly disposed of since the start of the city’s Clean Syringe
Presenting the Safe Point San Diego Clean Syringe Exchange Program
Annual Report for fiscal year 2014 Dunford then asked Council members to
imagine the stack of 2.5 million dirty needles: “Put that at Petco Park and see what kind of pile you’d be looking at.”
Dunford told members of the Public Safety & Livable Neighborhoods
Committee the program has taken in 405,416 dirty needles just in the
last fiscal year. He said the program has collected 276,958 more
syringes than clean ones distributed to drug addicts.
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers
Squibb Company (NYSE:BMY) today announced that the U.S. Food and
Drug Administration (FDA) has issued a Complete Response Letter (CRL)
regarding the New Drug Application (NDA) for daclatasvir, an NS5A
complex inhibitor, in combination with other agents for the treatment of
hepatitis C (HCV).
The initial daclatasvir NDA submitted to the FDA focused on its use in
combination with asunaprevir, an NS3/4A protease inhibitor. Given the
withdrawal of asunaprevir by Bristol-Myers Squibb in October, the FDA is
requesting additional data for daclatasvir in combination with other
antiviral agents for the treatment of HCV. Bristol-Myers Squibb is in
discussions with the FDA about the scope of these data.
“Despite the recent advances in the treatment of hepatitis C there
remain significant areas of unmet high need in this disease area,” said Francis
Cuss, Executive Vice President and Chief Scientific Officer, R&D,
Bristol-Myers Squibb. “Our commitment remains to make daclatasvir-based
regimens available to help these difficult-to-treat patients achieve
cure, and we will continue to collaborate with the FDA to bring
daclatasvir to patients in the U.S. as quickly as possible.”
Ongoing Daclatasvir Clinical Development
Bristol-Myers Squibb is dedicated to the ongoing clinical development
program for daclatasvir, a potent, pan-genotypic NS5A complex inhibitor (in
vitro), which is currently being investigated globally in multiple
treatment regimens for HCV patients with high unmet need. The company
continues to progress its daclatasvir clinical trial program focused on
difficult-to-treat patients, including pre- and post-liver transplant
(ALLY-1), HCV patients co-infected with HIV (ALLY-2) and patients with
genotype 3 (ALLY-3). The Phase 3 UNITY studies investigating
Bristol-Myers Squibb’s investigational all-oral fixed-dose-combination
DCV-TRIO regimen (daclatasvir/asunaprevir/beclabuvir) are also ongoing
and include study populations of non-cirrhotic naïve, cirrhotic naïve
and previously treated patients.
– Bristol-Myers Squibb Co on Wednesday said U.S. regulators had
declined to approve the use of its experimental treatment for hepatitis
C, daclatasvir, in combination with other antiviral drugs.
Bristol-Myers said it had
initially sought permission from the U.S. Food and Drug Administration
to market the drug, a so-called NS5A inhibitor, in combination with
asunaprevir, one of the New York-based company’s experimental medicines.
Bristol-Myers abandoned its U.S. marketing application for asunaprevir
in October because of potential competition from more potent drugs,
leaving the FDA without data to gauge the effectiveness of daclatasvir
as part of a combination regimen.
The majority of carriers are immigrants from the former Soviet Union
Hepatitis C carriers — the majority of them immigrants from the former
Soviet Union — are a ticking bomb, as there are drugs that cure the
disease but they are not in the basket of health services, according to
experts who spoke at the Knesset Immigration and Absorption Committee on
Tuesday. There are an estimated 100,000 carriers of hepatitis C who are
unaware of their condition. Decades after infection, will trigger
cirrhosis and liver cancer in about one-fifth of them.
The session was held to mark Israel Hepatitis Awareness Day. Hepatitis
C, very common among baby boomers, immigrants and intravenous drug
users, is one of the most dangerous forms of hepatitis as, unlike
hepatitis B, there is no vaccine to protect against it. Carrying the
virus is very common among people who received blood transfusions before
1992 when donations were tested, FSU immigrants and intravenous drug
users. Every year, some 1.4 million people die from the chronic types of
hepatitis. In Israel, liver diseases are the 12th most common killers
of Israelis, causing three deaths per 100,000 male residents and 1.7
Committee chairman MK Yoel Razbozov of Yesh Atid, who initiated the
session, charged that the Health Ministry lacks exact and current data
on the number of Israelis with chronic hepatitis B and C or on the
economic costs of the diseases.